A Protein Tyrosine Phosphatase 1B Inhibitor as a Potential Drug Against Prostate Cancer

Advances in developing new anticancer drugs continue, and one of the new therapeutic targets to reach is the Protein Tyrosine Phosphatase 1B (PTP1B), due to its functions, which are related to prognosis in a variety of types of cancer, and this protein is strongly related to tumor proliferation, migration, and apoptosis. This study evaluated a potential PTP1B ligandthe PT2 compound, whwhichup proposed as a compreviously pound directed to interact with the PTP1B´s activPTP1B´s in this wayto d,evelop a dru,g that could regulate the PTP1B´s functPTP1B´s The aim of this research is to evaluate the effects of the PT2 compound on PTP1B´s functions in prostate cancer cells (PC3) by in vitro cultures. We determined a regulation on messengers in PC3 cells, due to a regulation in the expression of p-FAK, p-P70S6K, and Glut-1; these proteins were correlated to decrease the function of PTP1B by the PT2 compound, whose effect is proportional to the concentration of the PT2 compound and cell. These results were determined by western blot, glucose uptake, and wound closure assays. We propose that the PT2 compound has a high probability of being selective for PTP1B, with an antimigration effect, allowing us to continue the evaluation. We also propose that this compound is likely to be used for security purposes in humans. These results showed the high potential of this compound as a new anticancer drug.